Every 8-K that INTERPACE BIOSCIENCES INC (IDXG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IDXG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IDXG filings page.
INTERPACE BIOSCIENCES, INC. (IDXG) approved and is implementing a 1-for-5 reverse stock split of its common stock. Stockholders authorized the board on August 20, 2026 to choose a ratio between 1:2 and 1:10, and the board set the final ratio at 1-for-5.
The reverse split becomes effective at 12:01 a.m. Eastern Time on August 27, 2026, when every five shares of common stock will be combined into one share, with no change to the $0.01 par value. Approximately 27.7 million shares outstanding will become approximately 5.5 million, while authorized shares remain unchanged, increasing potential headroom.
Fractional shares will not be issued and will instead be rounded up to the nearest whole share. The stock is expected to begin trading on a split-adjusted basis on OTCID on August 27, 2026, temporarily under ticker IDXGD for 20 trading days, with a new CUSIP of 46062X402. The company states the reverse split is primarily intended to help meet Nasdaq Capital Market minimum bid price requirements for a proposed uplisting.
Interpace Biosciences, Inc. (IDXG) filed an amended current report to document stockholder approval and adoption of its new 2026 Benefit Plans. At the August 20, 2026 annual meeting, stockholders approved the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan.
The 2026 Equity Incentive Plan replaces the company’s 2019 Equity Incentive Plan, and the 2026 Employee Stock Purchase Plan replaces the 2019 Employee Stock Purchase Plan, as amended. No further equity awards will be granted under the 2019 Equity Incentive Plan and no further purchases will occur under the 2019 ESPP. Detailed terms of the new plans are provided in the company’s July 7, 2026 definitive proxy statement and in plan forms incorporated by reference as exhibits.
INTERPACE BIOSCIENCES, INC. (IDXG) reported the results of its 2026 annual meeting of stockholders held on August 20, 2026. Stockholders approved all matters submitted to a vote, including the election of directors and several additional proposals.
Directors Vijay Aggarwal, Thomas W. Burnell, Joseph D. Keegan, Ph.D., Fortunato Ron Rocca, and Stephen J. Sullivan each received over 24.4 million votes in favor, with no votes against and between 135,575 and 808,652 votes withheld, plus 1,347,136 broker non-votes for each nominee.
Interpace Biosciences reported Q2 2026 results showing improved profitability and margins as a thyroid-only diagnostics business. Revenue was $9.1 million, down 1% from $9.2 million reported a year earlier but up 9% from $8.4 million on a Pro Forma basis excluding the discontinued PancraGEN® business. Gross profit margin rose to 62% from 57% reported and 54% Pro Forma, and operating income was $0.3 million compared with operating losses in the prior-year quarter. Income from continuing operations was $0.3 million versus a $0.5 million loss a year ago.
Adjusted EBITDA increased to $0.7 million, or 8% of revenue, from $0.2 million on a Pro Forma basis, aided by higher thyroid revenue and efficiency gains, despite approximately $0.2 million of non-recurring professional fees. For the first six months of 2026, revenue was $18.2 million, up 12% from the prior-year Pro Forma period, with a 64% gross margin and $1.1 million of income from continuing operations. Adjusted EBITDA for the half-year was $2.3 million, or 13% of revenue.
The company highlighted a debt-free balance sheet, thyroid test volume growth, and operational metrics such as improved days sales outstanding and turnaround time. It also outlined a pancreatic cancer testing program in development and plans to add a Chief Scientific Officer in September 2026.
Interpace Biosciences reported profitable first-quarter 2026 results while continuing its thyroid-only focus. Revenue was $9.0 million, down from $11.5 million a year earlier but up from $7.9 million on a Pro Forma basis that excludes the discontinued PancraGEN business. Gross margin improved to 65%, compared with 59% on a Pro Forma basis, reflecting better pricing and cost control in thyroid testing.
Income from continuing operations was $0.8 million versus $1.8 million a year ago, but higher than $0.4 million on a Pro Forma basis. Adjusted EBITDA reached $1.6 million, or 17% of revenue, up from $0.8 million and 10% on a Pro Forma basis. The company reaffirmed 2026 guidance for approximately 16% year-over-year thyroid revenue growth and highlighted higher average revenue per test, more accounts, and faster turnaround times. Interpace ended the quarter with $2.6 million in cash and no debt.
Interpace Biosciences reported Q4 2025 revenue of $9.2 million and full-year 2025 revenue of $38.7 million, both down versus 2024 but up versus thyroid-only pro forma comparisons. Income from continuing operations jumped to $22.8 million in Q4 and $25.0 million for the year, mainly from a one-time, non-cash tax-related accounting adjustment that released a deferred tax valuation allowance.
Thyroid testing remained the growth engine, with 2025 thyroid revenue up 21% and volume up 13% year-over-year. The company completed its shift to a thyroid-only diagnostics model, paid off its debt in Q4 2025, improved cash to $2.5 million, and moved stockholders’ equity from a deficit to a positive $22.4 million at year-end.
Interpace Biosciences, Inc. filed a current report describing preliminary, unaudited revenue for the year ended December 31, 2025, as outlined in a related press release.
The company also reported that all outstanding shares of its Series C Preferred Stock were converted into shares of its common stock, simplifying its equity structure. The press release dated January 20, 2026 is furnished as an exhibit to the report and is not treated as filed for purposes of liability under the Exchange Act.
Interpace Biosciences, Inc. reported that on December 3, 2025 it fully repaid its outstanding term loan facility with BroadOak Capital Partners before the loan’s scheduled maturity. This means the company has cleared that specific debt obligation earlier than required, which can simplify its capital structure and reduce future interest payments. The update was shared through a press release attached as an exhibit, providing more detail on the repayment and its context for the business.
Interpace Biosciences, Inc. (IDXG) furnished an 8-K under Item 2.02 announcing results of operations and financial condition for the quarter ended September 30, 2025. The company issued a press release, included as Exhibit 99.1, providing the full details.
The information in Item 2.02, including Exhibit 99.1, is being furnished and is not deemed “filed” for purposes of Section 18 of the Exchange Act. The filing also lists the Cover Page Interactive Data File as Exhibit 104.